Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical versus continuous infusion tranexamic acid for bleeding reduction after pediatric open-heart surgery
IRCT20200429047236N1Phase 2Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of tranexamic acid in Cardiovascular Malformation (CVM), atrial septal defect (ASD), Ventricular Septal Defect (VSD) and 1 more (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Hemoglobin changes and Rate of bleeding. Started Oct 2019; status: completed.
02
Drugs
tranexamic acid
03
Conditions
Cardiovascular Malformation (CVM)atrial septal defect (ASD)Ventricular Septal Defect (VSD)atrioventricular canal defect (AVSD)
Beyond the preview
Go deeper on IRCT20200429047236N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200429047236N1.